NCT06645704View on ClinicalTrials.gov

An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

December 10, 2024

Study Completion Date

December 10, 2024

Conditions
Healthy Participants
Interventions
DRUG

EP262

Single dose of \[14C\]-EP262 administered orally.

Trial Locations (1)

21201

Pharmaron Clinical Pharmacology Center (CPC), Baltimore

Sponsors
All Listed Sponsors
lead

Escient Pharmaceuticals, Inc

INDUSTRY

NCT06645704 - An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration | Biotech Hunter | Biotech Hunter